Reference

Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting

Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting. Baos, V.Several substances are used for example 144034-80-0 which is its cas registry number.; Serrano, A.; Torrecilla, M.; Bertral, C.; Caloto, M. T.; Nocea, G.; Gerth, W. C. (I-MAX Study Group; Healthcare Clinic, Madrid, Spain). International Journal of Clinical Practice, 57(9), 761-768 (English) 2003 Blackwell Publishing Ltd. CODEN: IJCPF9. ISSN: 1368-5031. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The purpose of this open-label study was to compare rizatriptan with usual non-triptan therapy for migraine in patients who had never received a triptan. Patient-reported outcomes were examd. for a prestudy migraine attack and after three consecutive study attacks, the first and third treated with rizatriptan 10 mg wafer and the second with usual non-triptan therapy. A total of 97 patients (83% women; mean age 39 yr) completed the study. Two-thirds of patients reported severe or total disability during migraine attacks. All comparisons between rizatriptan therapy and usual non-triptan therapy significantly favored rizatriptan (p ￡ 50.01). Headache relief by 2 h was reported by 78 - 83% of patients after rizatriptan and by 46 - 48% of patients after usual therapy; 41 - 47% arid 12 - 18%, resp., were pain free at 2 h. Patient satisfaction and migraine-specific quality-of-life scores were also significantly better for attacks treated with rizatriptan. At study end, 62% and 17% of patients were very or completely satisfied with rizatriptan and usual non-triptan therapy, resp. Among those patients who worked for pay, therapy with rizatriptan significantly reduced absenteeism and improved the amt. and quality of time at work compared with usual non-triptan therapy. Allowing patients to have experience with rizatriptan may improve the level of medical care for migraine attacks. .

Rizatriptan in the treatment of migraine

All Rights Reserved. Rizatriptan in the treatment of migraine. Lainez, Miguel J. A. (Department of Neurology, University Clinic Hospital, University of Valencia, Valencia, Spain). Neuropsychiatric Disease and Treatment, 2(3), 247-259 (English) 2006 Dove Medical Press (NZ) Ltd. CODEN: NDTEAZ. ISSN: 1176-6328. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Migraine is a common, disabling disorder assocd. with considerable personal and societal burden. Current guidelines recommend triptans for the acute treatment of migraine unlikely to respond to less effective therapies. Rizatriptan is a second-generation triptan available in tablet or orally disintegrating tablet (wafer) formulations that offers several advantages over other members of its class. Rizatriptan is rapidly absorbed from the gastrointestinal tract and achieves max. plasma concns. more quickly than other triptans, providing rapid pain relief. Clin. trials have shown that rizatriptan is at least as effective or superior to other oral migraine-specific agents in the acute treatment of migraine, and has more consistent long-term efficacy across multiple migraine attacks. Rizatriptan has a favorable tolerability profile, and patients have reported greater satisfaction and a preference for rizatriptan over other migraine-specific agents. Improvements in quality of life reported with rizatriptan are consistent with its favorable efficacy and tolerability profiles. Notably, multi-attribute decision models that combine clin.In this experiment, several chemicals are used like 144034-80-0 data with patient- and physician-reported treatment preferences have identified rizatriptan as one of three triptans closest to a hypothetical "ideal". The efficacy and tolerability of rizatriptan for the acute treatment of migraine have thus been well established. .